FTC backs antitrust challenge to Amgen’s Enbrel patent deal

Legal Atlas Watchline · August 21, 2026

What happened

Key facts FTC filed an amicus brief

Why it matters

Key facts The case concerns Amgen and Enbrel

The details

Key facts Enbrel is used to treat rheumatoid arthritis and other inflammatory conditions

Read the full report

Atlas Watchline The Federal Trade Commission filed an amicus brief in a Fourth Circuit appeal, saying commercial deals… Read on Atlas Watchline Read on Atlas Watchline